Life Sciences

  • August 04, 2026

    Biotech Founder Claims He Was Excluded From GSK Deal

    The co-founder of a defunct biotech company said his business partners froze him out of an asthma drug venture that was eventually snapped up by GlaxoSmithKline for $1.4 billion, in a complaint filed in Massachusetts state court.

  • August 04, 2026

    Saxena White Seeks To Lead GeneDX AI Acquisition Row

    Saxena White PA has asked a Connecticut federal court to appoint it as lead counsel in a securities class action accusing the biopharma company GeneDX Holdings Corp. of misrepresenting the benefits of a $51 million acquisition, and to name two public retirement systems as lead plaintiffs.

  • August 04, 2026

    Fed. Circ. Won't Reopen Lidocaine Patch Patent Suit

    The Federal Circuit on Tuesday declined to reinstate a suit accusing Florida pharmaceutical manufacturer Aveva Drug Delivery Systems of infringing a trio of lidocaine patch patents, shooting down arguments that a lower court misinterpreted key patent language.

  • August 04, 2026

    Workers Say Trump's Gold Card Lets Rich Jump Visa Line

    Professional, skilled workers seeking employment-based visas urged a D.C. federal judge not to toss their lawsuit challenging the gold card visa program, arguing they will suffer injury because the expedited application allows wealthy individuals to skip ahead in line.

  • August 04, 2026

    Bellwether Jury Awards $88M In Covidien Hernia Mesh Trial

    A Massachusetts federal jury awarded $88 million Tuesday to a man who claimed he was injured by a Covidien LP-made hernia mesh, in the first case to reach a verdict of thousands pending against the Medtronic unit.

  • August 03, 2026

    Albertsons Says Wash. Slow To Warn Of Bad Drug Prescribers

    Washington regulators didn't notify pharmacies or patients about doctors' potentially improper opioid prescribing until months after receiving complaints, Albertsons' counsel told a Seattle judge Monday, as the bench trial over Washington's claims the pharmacy chain helped fuel the state's overdose crisis entered its fourth week.

  • August 03, 2026

    Calif. Justices Back Gilead Over Nondefective Drug Liability

    The California Supreme Court on Monday held that Gilead Sciences Inc. shouldn't face a negligence claim alleging it declined to market a safer HIV drug in order to maximize profits from an older drug with more harmful side effects, rejecting a novel theory that would expose drugmakers to broader liability.

  • August 03, 2026

    7th Circ. Backs OB-GYN's 10-Year Healthcare Fraud Sentence

    The Seventh Circuit has upheld a 10-year prison sentence for a former obstetrician-gynecologist over a multimillion-dollar healthcare fraud scheme, saying the district judge made no clear error in applying an enhancement to her sentence for performing invasive and medically unnecessary procedures on patients without their informed consent.

  • August 03, 2026

    Novo False-Ad Claims Against Telehealth Co. Fail, For Now

    A New York federal court tossed a false advertising suit by Novo Nordisk against a telehealth company that markets compounded weight loss medications, finding the pharmaceutical giant failed to point to literal or implied false statements made by the company.

  • August 03, 2026

    4 Firms Steer Curium's $8B Lantheus Take-Private Deal

    Private equity-backed radiopharmaceutical company Curium on Monday announced plans to acquire fellow radiopharmaceutical company Lantheus Holdings Inc. in an $8 billion take-private deal built by four law firms.

  • August 03, 2026

    Sandoz Settles States' Generics Price-Fixing Cases For $450M

    Sandoz reached a settlement with a coalition of state enforcers on Monday, agreeing to pay $450 million to end claims against it in several cases targeting alleged price-fixing in the generic-drug industry.

  • August 03, 2026

    Baker Botts Hires Litigators In DC And London

    Baker Botts LLP has hired two litigators who focus on representing companies in highly regulated and technically sophisticated industries as partners in its offices in Washington, D.C., and London, the firm announced Monday.

  • August 03, 2026

    Pfizer COVID Vaccine Suit Needs 3-Judge Court, Panel Finds

    The D.C. Circuit has revived a couple's suit against Pfizer Inc., federal officials and a pediatrician's office alleging their child died after receiving the COVID-19 vaccine, saying federal law required a three-judge court to decide motions to dismiss, not the single judge who tossed the case.

  • August 03, 2026

    KKR Buying Integer For $5.7B In Kirkland, Davis Polk-Led Deal

    KKR said Monday that it will acquire medical device company Integer Holdings Corp. in an all-cash transaction with a roughly $5.7 billion enterprise value, with Kirkland & Ellis LLP and Davis Polk & Wardwell LLP advising on the transaction. 

  • August 03, 2026

    Bath Product Maker Vi-Jon Hits Ch. 11 With $25M Talc Deal

    Private-label dry bath product maker Vi-Jon LLC filed for Chapter 11 protection in Delaware with a proposed plan to channel talc injury claims into a trust to be funded by $25 million of cash and the contribution of certain insurance rights.

  • August 03, 2026

    Former Gates Foundation Deputy GC Joins Arnold & Porter

    The former deputy counsel of the Gates Foundation has joined Arnold & Porter Kaye Scholer LLP's life sciences and technology transactions teams in the corporate and finance practice, the firm announced Monday.

  • July 31, 2026

    Law360 Names 2026's Top Attorneys Under 40

    Law360 is pleased to announce the Rising Stars of 2026, our list of more than 160 attorneys under 40 whose legal accomplishments belie their age.

  • July 31, 2026

    Mich. Justices' Ruling Will Allow Eli Lilly Price-Fixing Probe

    A split Michigan Supreme Court Friday overturned two of its prior rulings that the majority determined had wrongly expanded an exemption in the Michigan Consumer Protection Act, opening the door for the state's attorney general to take action against misconduct in a range of industry sectors.

  • July 31, 2026

    Appeals Courts Upheld Similar E-Cig Regs, Pa. Tells Court

    There's no good reason to block Pennsylvania from enforcing a statewide ban on most vape products, the commonwealth has told a Pennsylvania federal court, saying many appeals courts across the country have come to the same conclusion that such laws are constitutional.

  • July 31, 2026

    Lab, Ex-CEO, Fla. Resident To Pay $36M Over Kickback Claims

    A Texas-based laboratory, its former CEO and a Florida businessman have each entered into settlements with the U.S. government totaling $36.4 million to resolve claims they paid kickbacks and billed Medicare and Medicaid for unnecessary medical genetic testing, in violation of the False Claims Act.

  • July 31, 2026

    Fed. Circ. Says Leica's Filtered Light Skirts U. Mich. Patent

    In a dispute centered on how laser light is used in fluorescence technology, a unanimous Federal Circuit panel said on Friday that Leica Microsystems did not infringe on a University of Michigan patent, affirming the decision of a federal court in California.

  • July 31, 2026

    TRESemme Hair Loss Suit Filed 2 Years Too Late, Judge Finds

    A New York federal judge has thrown out a woman's suit claiming TRESemme shampoo caused her to suffer hair loss, saying evidence turned up in discovery shows she filed her claims nearly two years too late.

  • July 31, 2026

    Thermo Fisher Says Ex-VP Took 'Know-How' To Rival

    A former Thermo Fisher Scientific Inc. executive broke a noncompete agreement when she left for a position that will make her responsible for building a rival firm's sterile manufacturing business in direct competition with her old company, according to a case removed to North Carolina federal court Friday.

  • July 31, 2026

    End In Sight For Ovarian Cancer Patients With $5.5B+ J&J Deal

    The $5.5 billion global deal over talc ovarian cancer allows women to move past recent court setbacks requiring them to provide experts who can show a causal link between their disease and use of talc, and for defendant J&J to close a decade of litigation that included judicially criticized gambits to spin off liability through bankruptcy maneuvers.

  • July 31, 2026

    J&J's $25M Talc Appeal Can Advance, Conn. Panel Rules

    A Connecticut appeals court has advanced Johnson & Johnson's challenge to a $25 million talc trial judgment, denying a Massachusetts real estate developer's attempt to dismiss the appeal based on what he argued was a late-filed brief.

Expert Analysis

  • Opinion

    AI Presents A Make-Or-Break Moment For Outside Counsel

    Author Photo

    The rapid adoption of artificial intelligence by corporate legal departments is forcing a long-overdue reset of the relationship between inside and outside counsel, and introducing a significant opportunity to shed frustrating inefficiencies and strengthen collaboration for firms willing to embrace the shift, says Intel Chief Legal Officer April Miller Boise.

  • Opinion

    USPTO Has A Chance To Correct Double-Patenting Doctrine

    Author Photo

    Now that the issue of obviousness-type double patenting is front and center before the U.S. Patent and Trademark Office's Appeals Review Panel, the agency should put an end to the practice of rejecting earlier-expiring patents in favor of later-expiring ones, say attorneys at Orrick.

  • Navigating Life Sciences Deals Amid Heightened Scrutiny

    Author Photo

    With pricing reform initiatives, national security legislation and evolving trade policy currently contributing to meaningful uncertainty for life sciences companies, it is important to proactively structure deals to avoid downstream complications, say attorneys at Cooley.

  • Series

    Watching Hallmark Movies Makes Me A Better Lawyer

    Author Photo

    I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.

  • New Orphan Drug Law Provides A Key Fix For Pharma Cos.

    Author Photo

    The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.

  • When Trade Secret Litigation And Criminal Law Collide

    Author Photo

    An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.

  • Opinion

    PTAB Needs Reform To Protect Inventors From Larger Cos.

    Author Photo

    The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.

  • FDA User Fee Talks Offer Clues On Upcoming Reforms

    Author Photo

    As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.

  • Moderna Case Highlights Overlooked Hurdle In Biopharma IP

    Author Photo

    The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.

  • FDA Framework For Personalized Therapies Raises Questions

    Author Photo

    The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.

  • Emissions Permits May Not Override Pollution Exclusions

    Author Photo

    Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.

  • 5 Tips For Navigating Your Firm's All-Attorney Summit

    Excerpt from Practical Guidance
    Author Photo

    Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.

  • Series

    Coaching Soccer Makes Me A Better Lawyer

    Author Photo

    Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.

  • Series

    Law School's Missed Lessons: The Human Element

    Author Photo

    Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.

  • Avoid The Unexpected When Drafting License Agreements

    Author Photo

    The Delaware Court of Chancery's recent decision in Commave v. Zevrain raises several practice points for attorneys drafting commercial contracts, underscoring the importance of considering anti-assignment provisions, specific exclusions and potential carveouts when drafting license agreements or other commercial contracts, say attorneys at Hogan Lovells.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.